| Type | Title | Date Released | |
|---|---|---|---|
DEFA14A | Form DEFA14A | ||
DEF 14A | Form DEF 14A | ||
4 | Krammer Anja B (Reporting) | ||
4 | Lindsay Mark F. (Reporting) | ||
4 | Green Ralph Elias (Reporting) | ||
PRER14A | Form PRER14A | ||
8-K | Nasdaq Confirms Compliance with $2.5 Million Stockholders’ Equity Requirement Following Strategic Acquisition and Preferred Stock Issuance | ||
PRE 14A | Form PRE 14A | ||
8-K | Acquisition Adds 11% SOD Sciences Stake, 50% Pseudohypoxia Test Interest and Potential Access to 325,000 Patients | ||
8-K | Vivos Therapeutics Agrees to Acquire Stake in SOD Sciences and Co-Ownership of Pseudohypoxia Test | ||
8-K | Vivos Therapeutics Changes Independent Registered Public Accounting Firm to Haynie & Company | ||
4 | SOKOLOW LEONARD J (Reporting) |